Collins Richard Alexander sells Dexcom (DXCM) shares worth $171,599

Published 18/11/2025, 00:00
Collins Richard Alexander sells Dexcom (DXCM) shares worth $171,599

Director Richard Alexander Collins reported selling 2,906 shares of DEXCOM INC (NASDAQ:DXCM) common stock on November 14, 2025. The shares were sold at a price of $59.05, totaling $171,599. The transaction occurred near DXCM’s current trading price of $58.47, with the stock down nearly 25% year-to-date according to InvestingPro data.

Following the transaction, Collins directly owns 5,074 shares of Dexcom. Additionally, the Richard A. Collins Revocable Trust, for which Collins serves as trustee, holds 35,088 Dexcom shares. Despite the insider sale, InvestingPro analysis suggests Dexcom is currently trading below its Fair Value, with analysts setting a consensus high target of $112.

The sale was executed under a pre-arranged 10b5-1 trading plan adopted by the Richard A. Collins Revocable Trust on August 7, 2025. Dexcom maintains a "GREAT" financial health score despite its stock volatility, with the company remaining profitable over the last twelve months. Discover more insights in Dexcom’s comprehensive Pro Research Report, available with 1,400+ other top stocks on InvestingPro.

In other recent news, DexCom reported its third-quarter earnings for 2025, surpassing analysts’ expectations with an earnings per share (EPS) of $0.61 compared to the forecasted $0.57. The company also reported revenue of $1.21 billion, exceeding the anticipated $1.18 billion. This represents a 20% year-over-year organic growth, with U.S. revenue increasing by 21% and international revenue growing by 18%. Despite these positive results, several analyst firms have adjusted their price targets for DexCom. Bernstein lowered its price target to $84, citing valuation concerns, while Piper Sandler reduced its target to $75 due to growth concerns. BTIG also adjusted its target to $85, maintaining a Buy rating, and Canaccord Genuity set its target at $99, noting quality cost issues. These adjustments come even as DexCom delivered a strong revenue beat but missed expectations on gross and operating margins.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.